Enriching CEOs, Endangering Patients
A new online petition drive is protesting the incredibly high prices that enormously overpaid pharmaceutical CEOs charge for cancer drugs.
A new online petition drive is protesting the incredibly high prices that enormously overpaid pharmaceutical CEOs charge for cancer drugs.
The basic idea behind legislation now pending in our smallest state: The taxes we pay should bankroll quality public services, not grand fortunes.
Should America’s taxpayers be subsidizing all those millions in compensation that CEOs are collecting? At least some members of Congress don’t think so.
The New York Times and the Washington Post have done some solid reporting on inequality. But this past week doesn’t rank among their finest moments.